Skip to main content
. 2016 Dec 1;292(2):706–722. doi: 10.1074/jbc.M116.749663

FIGURE 7.

FIGURE 7.

Tamoxifen-inducible loss of EZH2 results in heightened intestinal immune reactivity. A–D, demonstration of weight change (A), clinical disease activity index (DAI, B), colon length (C), and blinded histologic inflammatory index (D) in tamoxifen-treated CRE × EZH2 fl/fl animals versus tamoxifen-treated CRE EZH2 WT/WT controls exposed to 3% DSS. E, representative colon histologic section demonstrating significant inflammation and ulceration. Statistical significance for weight change was determined using the Holm-Sidak method, with α = 5.000% (p < 0.05). Each time point was analyzed individually without assuming a consistent S.D. For colon length and histologic and disease activity index, significance was determined using a non-parametric, unpaired t test of significance (Mann-Whitney), p < 0.05. The data are generated from n = 8 animals, 4/group. *, p ≤ 0.05; ***, p ≤ 0.0001.